Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, Dekker CL, Didierlaurent AM, Graham BS, Martin SD, Molrine DC, Perlman S, Picard-Fraser PA, Pollard AJ, Qin C, Subbarao K, Cramer JP. Lambert PH, et al. Among authors: didierlaurent am. Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25. Vaccine. 2020. PMID: 32507409 Free PMC article.
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data.
Munoz FM, Cramer JP, Dekker CL, Dudley MZ, Graham BS, Gurwith M, Law B, Perlman S, Polack FP, Spergel JM, Van Braeckel E, Ward BJ, Didierlaurent AM, Lambert PH; Brighton Collaboration Vaccine-associated Enhanced Disease Working Group. Munoz FM, et al. Among authors: didierlaurent am. Vaccine. 2021 May 21;39(22):3053-3066. doi: 10.1016/j.vaccine.2021.01.055. Epub 2021 Feb 23. Vaccine. 2021. PMID: 33637387 Free PMC article. Review.
Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19 - A Comprehensive Analysis.
Meyer B, Martinez-Murillo PA, Lemaitre B, Blanchard-Rohner G, Didierlaurent AM, Fontannaz P, Eugercios Manzanas C, Lambert PH, Loevy N, Kaiser L, Sartoretti J, Tougne C, Villard J, Huttner A, Siegrist CA, Eberhardt CS. Meyer B, et al. Among authors: didierlaurent am. Front Immunol. 2022 May 2;13:841009. doi: 10.3389/fimmu.2022.841009. eCollection 2022. Front Immunol. 2022. PMID: 35585978 Free PMC article.
Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.
Vetter P, Eberhardt CS, Meyer B, Martinez Murillo PA, Torriani G, Pigny F, Lemeille S, Cordey S, Laubscher F, Vu DL, Calame A, Schibler M, Jacquerioz F, Blanchard-Rohner G, Siegrist CA, Kaiser L, Didierlaurent AM, Eckerle I. Vetter P, et al. Among authors: didierlaurent am. mSphere. 2020 Nov 11;5(6):e00827-20. doi: 10.1128/mSphere.00827-20. mSphere. 2020. PMID: 33177214 Free PMC article.
Immunological Assessment of Pediatric Multisystem Inflammatory Syndrome Related to Coronavirus Disease 2019.
Grazioli S, Tavaglione F, Torriani G, Wagner N, Rohr M, L'Huillier AG, Leclercq C, Perrin A, Bordessoule A, Beghetti M, Schmid JP, Vavassori S, Perreau M, Eberhardt C, Didierlaurent A, Kaiser L, Eckerle I, Roux-Lombard P, Blanchard-Rohner G. Grazioli S, et al. J Pediatric Infect Dis Soc. 2021 Aug 14;10(6):706-713. doi: 10.1093/jpids/piaa142. J Pediatric Infect Dis Soc. 2021. PMID: 33180935 Free PMC article.
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study.
Madelon N, Lauper K, Breville G, Sabater Royo I, Goldstein R, Andrey DO, Grifoni A, Sette A, Kaiser L, Siegrist CA, Finckh A, Lalive PH, Didierlaurent AM, Eberhardt CS. Madelon N, et al. Among authors: didierlaurent am. Clin Infect Dis. 2022 Aug 24;75(1):e1037-e1045. doi: 10.1093/cid/ciab954. Clin Infect Dis. 2022. PMID: 34791081 Free PMC article.
Immunogenicity and safety of a booster dose of an investigational adjuvanted polyprotein HIV-1 vaccine in healthy adults and effect of administration of chloroquine.
Leroux-Roels G, Bourguignon P, Willekens J, Janssens M, Clement F, Didierlaurent AM, Fissette L, Roman F, Boutriau D. Leroux-Roels G, et al. Among authors: didierlaurent am. Clin Vaccine Immunol. 2014 Mar;21(3):302-11. doi: 10.1128/CVI.00617-13. Epub 2014 Jan 3. Clin Vaccine Immunol. 2014. PMID: 24391139 Free PMC article. Clinical Trial.
Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab.
Madelon N, Heikkilä N, Sabater Royo I, Fontannaz P, Breville G, Lauper K, Goldstein R, Grifoni A, Sette A, Siegrist CA, Finckh A, Lalive PH, Didierlaurent AM, Eberhardt CS. Madelon N, et al. Among authors: didierlaurent am. JAMA Neurol. 2022 Apr 1;79(4):399-404. doi: 10.1001/jamaneurol.2022.0245. JAMA Neurol. 2022. PMID: 35212717 Free PMC article.
Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.
Burny W, Marchant A, Hervé C, Callegaro A, Caubet M, Fissette L, Gheyle L, Legrand C, Ndour C, Tavares Da Silva F, van der Most R, Willems F, Didierlaurent AM, Yarzabal J; ECR-008 study group. Burny W, et al. Among authors: didierlaurent am. Vaccine. 2019 Mar 28;37(14):2004-2015. doi: 10.1016/j.vaccine.2019.02.015. Epub 2019 Mar 5. Vaccine. 2019. PMID: 30850240 Free article. Clinical Trial.
Longitudinal Analysis of Inflammatory Response to SARS-CoV-2 in the Upper Respiratory Tract Reveals an Association with Viral Load, Independent of Symptoms.
Vu DL, Martinez-Murillo P, Pigny F, Vono M, Meyer B, Eberhardt CS, Lemeille S, Von Dach E, Blanchard-Rohner G, Eckerle I, Huttner A, Siegrist CA, Kaiser L, Didierlaurent AM. Vu DL, et al. Among authors: didierlaurent am. J Clin Immunol. 2021 Nov;41(8):1723-1732. doi: 10.1007/s10875-021-01134-z. Epub 2021 Sep 28. J Clin Immunol. 2021. PMID: 34581925 Free PMC article.
80 results